Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug167 | Active COVID-19 disease Wiki | 0.71 |
| drug277 | Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19 Wiki | 0.71 |
| drug2505 | Placebo Wiki | 0.07 |
Navigate: Correlations HPO
There are 2 clinical trials
This is a phase 1 study in healthy subjects to evaluate the safety, tolerability and pharmacokinetics of single (Part A and B) and multiple (Part B) doses of inhaled TD-0903.
Description: Number and severity of treatment emergent adverse events
Measure: Safety and Tolerability of SAD of TD-0903: Adverse Events Time: Day 1 to Day 8Description: Number and severity of treatment emergent adverse events
Measure: Safety and Tolerability of MAD of TD-0903: Adverse Events Time: Day 1 to Day 14Description: Multiple PK variables of TD-0903 will be assessed during SAD and may include, but are not limited to: Area under the plasma concentration-time curve (AUC)
Measure: Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): AUC Time: Day 1 through Day 4Description: Multiple PK variables of TD-0903 will be assessed during SAD and may include, but are not limited to: Maximum observed concentration (Cmax)
Measure: Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Cmax Time: Day 1 through Day 4Description: Multiple PK variables of TD-0903 will be assessed during SAD and may include, but are not limited to: Time to reach maximum observed concentration (Tmax)
Measure: Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Tmax Time: Day 1 through Day 4Description: Multiple PK variables of TD-0903 will be assessed during MAD and may include, but are not limited to: Area under the plasma concentration-time curve (AUC)
Measure: Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): AUC Time: Day 1 through Day 9Description: Multiple PK variables of TD-0903 will be assessed during MAD and may include, but are not limited to: Maximum observed concentration (Cmax)
Measure: Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Cmax Time: Day 1 through Day 9Description: Multiple PK variables of TD-0903 will be assessed during MAD and may include, but are not limited to: Time to reach maximum observed concentration (Tmax)
Measure: Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Tmax Time: Day 1 through Day 9This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed COVID-19 associated acute lung injury and impaired oxygenation.
Description: Change from baseline in SaO2/FiO2 ratio
Measure: Part 2: SaO2/FiO2 ratio Time: Baseline, Day 7Description: Number of days the subject was not using invasive mechanical ventilation or non-invasive positive pressure ventilation
Measure: Part 2: Ventilator-free Days (VFDs) Time: Baseline through Day 28Description: Number of days the subject was not in the ICU
Measure: Part 2: Intensive Care Unit Free Days (ICU-free) Time: Baseline through Day 28Description: Area under the plasma concentration-time curve (AUC) in SaO2/FiO2 ratio
Measure: Part 2: AUC in SaO2/FiO2 ratio Time: Baseline through Day 7Description: Change from baseline in SaO2/FiO2 ratio
Measure: Part 2: SaO2/FiO2 ratio Time: Baseline, Day 5Description: Proportion of subjects with a SaO2/FiO2 ratio > 315
Measure: Part 2: SaO2/FiO2 ratio > 315 Time: Day 5, Day 7Description: Proportion of subjects discharged
Measure: Part 2: Subjects Discharged Time: Day 7, 14, 21 and 28Description: Time to hospital discharge
Measure: Part 2: Hospital Discharge Time: Baseline through up to Day 28Description: The subject mortality rate (all causes)
Measure: Part 2: Mortality Rate Time: Day 28Description: Change from baseline in the modified Borg Dyspnea Score. The modified Borg Dyspnea Score is based on a 10-point scale that measures shortness of breath. Scores range from 0 (nothing at all, no shortness of breath) to 10 (maximal shortness of breath).
Measure: Part 2: Modified Borg Dyspnea Score Time: Baseline through Day 7Description: Proportion of subjects in each category of the Clinical Status scale. The Clinical Status scale contains 6 different categories that are each assigned a numeric score. The values range from 1 (representing 'Not hospitalized'), 2 (hospitalized, not requiring supplemental oxygen), 3 (hospitalized, requiring low-flow oxygen supplementation), 4 (hospitalized, on non-invasive positive pressure ventilation or high-flow oxygen supplementation), 5 (hospitalized, on invasive mechanical ventilation, 6 (Death).
Measure: Part 2: Clinical Status Scale Time: Day 7, 14, 21 and 28Description: Proportion of subjects in each category of Vital Status, where the categories are defined as death, discharge, or hospitalized.
Measure: Part 2: Vital Status Time: Day 7, 14, 21 and 28Description: Proportion of subjects alive and free of ventilatory support
Measure: Part 2: Subjects alive and free of ventilatory support Time: Day 28Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports